🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →
S&P 500: 774.83 +0.7% NASDAQ 100: 756.20 +0.9% Dow Jones: 534.08 -0.5%

Acorn Capital Advisors - Q2 2026 13F Filings

AC

Acorn Capital Advisors, LLC

CIK: 0002054410
Address: New York New York 420 Lexington Avenue Suite 2626
$366.46 M
Portfolio Value
20
Assets Held
Reporting Period: Q2 2026
Filing Status:
Active
Last Updated: 08/14/2026

Portfolio Summary (Q2 2026)

View Full Portfolio Analysis

Top Buys

Q2 2026
1. KPTI Karyopharm Therapeutics
+$12.02 M
2. JBIO Jade Biosciences
+$4.44 M
3. AURA Aura Biosciences
+$2.37 M
4. ENGN Engene Therapeutics
+$2.2 M
5. CGON Cg Oncology
+$70,978.99

Top Sells

Q2 2026
1. TERN Terns Pharmaceuticals
−$92.06 M
2. CRDF Cardiff Oncology
−$2.85 M
3. QTTB Q32 Bio
−$1.26 M
4. X4 Pharmaceuticals
−$966,583
5. BCAX Bicara Therapeutics
−$29.69

Asset Allocation

Stocks/ETFs
+4.16%
$366.46 M 100.00%
Options
$0 0.00%
Debt
$0 0.00%
Other
$0 0.00%

Sector Allocation (Stocks)

Acorn Capital Advisors Q2 2026 Filing Summary

Acorn Capital Advisors, LLC filed its 13F report for Q2 2026 on August 14, 2026. The portfolio totaled 366.46 M reflecting a +4.16% change from the prior quarter, spanning 20 assets. The top 10 holdings comprised 90.2% of the portfolio, with Financials as the largest sector allocation. Quarterly activity included 1 new positions and 3 complete exits.

Report Type

Status

Data Summary

Items:

Total Value:

Actions

Issuer Name Class Value Shares Option Type

FAQs for Acorn Capital Advisors’s Q2 2026 Filing

Acorn Capital Advisors submitted their Form 13F-HR for the Q2 2026 period on 08/14/2026. This was the only submission for the quarter.

In the Q2 2026 filing, Acorn Capital Advisors reported a managed portfolio value of 366.46 M, consisting of 20 individual positions.

This page displays the raw filing documents. To see which stocks Acorn Capital Advisors bought or sold during Q2 2026, please visit Acorn Capital Advisors's Portfolio Analysis page.